SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?


To: Sam Citron who wrote (7537)12/18/2002 4:02:03 PM
From: Vector1  Read Replies (1) | Respond to of 52153
 
Sam, the answer is both. It will be used in some patients instead of Rit in patients who are multiple chemo refractory but mostly it will be used in patients that also fail Rit. The reason for this is that Rit is relatively nontoxic and is rapidly becomming the standard of care in conjunction with chemo.

V1